Effect of amikacin and prulifloxacin alternate application in the treatment of lung infections in ICU resistant acinetobacter bauman
10.3969/j.issn.1005-1678.2016.12.028
- VernacularTitle:阿米卡星与普卢利沙星交替应用对ICU内耐药鲍曼不动杆菌肺部感染的临床效果及安全性研究
- Author:
Lingmin ZHOU
;
Zhihui GUAN
;
Feifei SHAO
;
Xiaorong XIAO
- Keywords:
Amikacin;
Bauman;
drug resistant Acinetobacter;
pulmonary infection;
clinical effect
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):99-102
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Amikacin and prulifloxacin alternate application in the treatment of Lung infections in ICU resistant Acinetobacter Bauman.Methods 82 cases of Lung infections in ICU resistant Acinetobacter Bauman from August 2014 to August 2016 in our hospital were selected and randomLy divided into two groups, 41 cases in control group were given routine treatment, 41 cases in the experimental group were treated with Amikacin and prulifloxacin alternate application, and patients were treated continuous for two weeks.Levels of serum CRP, PCT, WBC, N%, SCR, BUN, AST, ALT, scores of APACHE II and CPIS and clinical efficacy were observed pre-and post-treatment.Results After two weeks, levels of serum CRP, PCT, WBC and N% in experimental group were significantly lower than control group, scores of APACHE II and CPIS were significantly lower than the control group, the total clinical efficiency was higher than the control group(P<0.05), and the levels of serum SCR, BUN, ALT, AST were lower, but had no statistically difference.Conclusion Amikacin and prulifloxacin alternate application in the treatment of Lung infections in ICU resistant Acinetobacter Bauman can reduce the patient's inflammatory reaction and the degree of infection.
